Researchers at the University of Texas at Austin, in collaboration with MedCara Pharmaceuticals, licensed the first testosterone nasal spray to alleviate symptoms of anxiety disorders.
With patents in the U.S. and Europe, its use allows for an alternative approach to treat anxiety disorders. Benzodiazepines, as do other sedatives with anxiolytic effects, results in unnecessary side effects. The nasal spray treats symptoms of severe anxiety without sedation.
“With this second U.S. patent and a first European patent supporting these claims, we’re one step closer to introducing a new weapon in the ongoing battle against mental illness,” said one of the study’s authors in a press release.
“A growing body of research points to testosterone’s importance in the etiology of anxiety disorders,” the author also stated.
“We are pleased to have partnered with UT Austin and Professor Josephs for the development of this technology. We expect that this new technology will allow us to develop therapeutic options that will complement our existing nasal technology. Acerus’ expertise in the formulation and development of nasally delivered active pharmaceutical ingredients, and more particularly testosterone, should enable Acerus to make this new technology a success,” states a press release by Acerus Pharmaceuticals Corporation.
A patent in China is in the works, with expectations for the nasal spray to be sold worldwide.
